Xp11 Translocation Renal Cell Carcinoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2022-02-16
Clinical Trial Update: Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) [Phase 2]
Phase II trial investigating sequential single-agent nivolumab followed by combination ipilimumab plus nivolumab in metastatic or unresectab…